GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Renal cell carcinoma usually presents as a solid mass ... intrinsic unilocular cystic growth (papillary cystic adenocarcinoma), intrinsic multilocular cystic growth, tumor necrosis resulting ...

Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Neuroendocrine Carcinoma.

Individuals with a family history of kidney cancer or certain genetic conditions, such as von Hippel-Lindau Disease or ...

This latest approval for Orpathys in NSCLC makes the drug available in both the first- and second-line settings.

comorbidities and risk of disease progression might influence their remaining renal function. In patients with known tumor multifocality, such as patients with a papillary histology or hereditary ...